获取途径

作者

Jinjing Liu Xin Yu Zhimian Wang Weiwei Liu Xiaochuan Liu Xiaoou Wang Menghao Zhang Yan Zhao Fengchun Zhang Hong Yang Wenjie Zheng

作者单位

National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China. Electronic address: zhengwj@pumch.cn. Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China. ² Department of Rheumatology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shan Dong 271000, China. ³ Department of Gastroenterology, Emergency General Hospital, Beijing, 100028, China. ⁴ Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, China. ⁵ Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Affiliations ¹ Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH)

刊名

Clinical immunology (Orlando, Fla.)

年份

2023

卷号

Vol.247

页码

109241

ISSN

1521-7035

关键词

Baricitinib Intestinal Behçet's disease Therapy.

摘要

Objectives: The pilot study aims to explore the efficacy and safety of baricitinib in treating refractory intestinal Behçet's disease . Methods: We consecutively enrolled patients with refractory intestinal BD from October 2020 to September 2022. They were treated with baricitinib 2-4 mg daily, with background glucocorticoids and immunosuppressants. Efficacy assessment included the global gastrointestinal symptom scores, the endoscopy scores, the Disease activity index for intestinal Behçet's di...更多

Objectives: The pilot study aims to explore the efficacy and safety of baricitinib in treating refractory intestinal Behçet's disease . Methods: We consecutively enrolled patients with refractory intestinal BD from October 2020 to September 2022. They were treated with baricitinib 2-4 mg daily, with background glucocorticoids and immunosuppressants. Efficacy assessment included the global gastrointestinal symptom scores, the endoscopy scores, the Disease activity index for intestinal Behçet's disease , and the inflammatory parameters. Side effects were recorded. Results: The thirteen patients had a median follow-up of eleven months, 76.92% patients achieved complete remission of global gastrointestinal symptom scores, and 66.7% had mucosal healing on endoscopy. The DAIBD scores decreased significantly, as well as the C-reactive protein level. Baricitinib showed a glucocorticoid-sparing effect, and the safety profile is favorable. Conclusion: Baricitinib might be a potential choice in treating refractory intestinal BD.收起

文献类型

期刊

浏览量

9